4170ae68-a4d2-4095-af47-4f981f7812a4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- ANGIOGENESIS+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- KRAS_SIGNALING_UP+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- E2F_TARGETS+0.200
- G2M_CHECKPOINT+0.200
- IL2_STAT5_SIGNALING+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.300
- PANCREAS_BETA_CELLS-0.300
- APOPTOSIS-0.200
- DNA_REPAIR-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- P53_PATHWAY-0.200
- PEROXISOME-0.200
- PI3K_AKT_MTOR_SIGNALING-0.200
- UV_RESPONSE_UP-0.200
- ESTROGEN_RESPONSE_EARLY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R263 | — | — | 0.788 |
| 2 | C3N-02192 | — | cohortMD2 | 0.765 |
| 3 | TCGA-BH-A0BL-01A-11R-A115-07 | — | D | 0.737 |
| 4 | TCGA-CV-5431-01A-01R-1514-07 | — | — | 0.719 |
| 5 | SRR934784 | — | — | 0.718 |
| 6 | MDT-AP-2796 | Med | Medulloblastoma | 0.711 |
| 7 | ERR2278875 | — | — | 0.705 |
| 8 | DRR168603 | — | — | 0.696 |
| 9 | TCGA-AQ-A04J-01A-02R-A034-07 | — | D | 0.690 |
| 10 | SRR8613814 | — | D | 0.689 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |